ZLD
vs
S
S&P/ASX 300
ZLD
Over the past 12 months, ZLD has underperformed S&P/ASX 300, delivering a return of -37% compared to the S&P/ASX 300's +6% growth.
Stocks Performance
ZLD vs S&P/ASX 300
Performance Gap
ZLD vs S&P/ASX 300
Performance By Year
ZLD vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Zelira Therapeutics Ltd
Glance View
Zelira Therapeutics Ltd. is a bio-pharmaceutical company. The company is headquartered in Perth, Western Australia. The company went IPO on 2003-07-28. The firm is focused on developing and clinically validating branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its prescription (Rx) business, including insomnia, autism and chronic non-cancer pain. The firm's lead product, Zenivol, is a cannabinoid-based medicine for the treatment of chronic insomnia. The firm is engaged in human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the United States. The company is also focused on pre-clinical research examining the effects of cannabinoids in breast, brain and pancreatic cancer, as well as research and development of cannabinoids to treat diabetes-associated cognitive decline. Its SprinjeneCBD toothpaste product is a hemp-derived, oral care product containing cannabinoids and based on the patented technology of blackseed oil and zinc.